•Journal•ISSN: 2287-4208
The World Journal of Men's Health
Korean Society for Sexual Medicine and Andrology
About: The World Journal of Men's Health is an academic journal published by Korean Society for Sexual Medicine and Andrology. The journal publishes majorly in the area(s): Medicine & Internal medicine. It has an ISSN identifier of 2287-4208. It is also open access. Over the lifetime, 1105 publications have been published receiving 9801 citations. The journal is also known as: WJMH.
Topics: Medicine, Internal medicine, Biology, Male infertility, Prostate cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This review highlights the mechanisms of ROS production, the physiological and pathophysiological roles of ROS in relation to the male reproductive system, and recent advances in diagnostic methods; it also explores the benefits of using antioxidants in a clinical setting.
Abstract: Infertility affects approximately 15% of couples trying to conceive, and a male factor contributes to roughly half of these cases. Oxidative stress (OS) has been identified as one of the many mediators of male infertility by causing sperm dysfunction. OS is a state related to increased cellular damage triggered by oxygen and oxygen-derived free radicals known as reactive oxygen species (ROS). During this process, augmented production of ROS overwhelms the body's antioxidant defenses. While small amounts of ROS are required for normal sperm functioning, disproportionate levels can negatively impact the quality of spermatozoa and impair their overall fertilizing capacity. OS has been identified as an area of great attention because ROS and their metabolites can attack DNA, lipids, and proteins; alter enzymatic systems; produce irreparable alterations; cause cell death; and ultimately, lead to a decline in the semen parameters associated with male infertility. This review highlights the mechanisms of ROS production, the physiological and pathophysiological roles of ROS in relation to the male reproductive system, and recent advances in diagnostic methods; it also explores the benefits of using antioxidants in a clinical setting.
868 citations
••
TL;DR: Several animal and human studies have shown sex differences in gut microbiota, and this work reviews these studies to discuss the sex-dependent differences as well as the possible mechanisms involved.
Abstract: Humans carry numerous symbiotic microorganisms in their body, most of which are present in the gut. Although recent technological advances have produced extensive research data on gut microbiota, there are various confounding factors (e.g., diet, race, medications) to consider. Sex is one of the important variables affecting the gut microbiota, but the association has not yet been sufficiently investigated. Although the results are inconsistent, several animal and human studies have shown sex differences in gut microbiota. Herein, we review these studies to discuss the sex-dependent differences as well as the possible mechanisms involved.
287 citations
••
TL;DR: This review focuses on the functions of AR in prostate cancer and the development of CRPC and promising new agents against CRPC.
Abstract: Androgen receptor (AR) is a steroid receptor transcriptional factor for testosterone and dihydrotestosterone consisting of four main domains, the N-terminal domain, DNA-binding domain, hinge region, and ligand-binding domain. AR plays pivotal roles in prostate cancer, especially castration-resistant prostate cancer (CRPC). Androgen deprivation therapy can suppress hormone-naive prostate cancer, but prostate cancer changes AR and adapts to survive under castration levels of androgen. These mechanisms include AR point mutations, AR overexpression, changes of androgen biosynthesis, constitutively active AR splice variants without ligand binding, and changes of androgen cofactors. Studies of AR in CRPC revealed that AR was still active in CRPC, and it remains as a potential target to treat CRPC. Enzalutamide is a second-generation antiandrogen effective in patients with CRPC before and after taxane-based chemotherapy. However, CRPC is still incurable and can develop drug resistance. Understanding the mechanisms of this resistance can enable new-generation therapies for CRPC. Several promising new AR-targeted therapies have been developed. Apalutamide is a new Food and Drug Administration-approved androgen agonist binding to the ligand-binding domain, and clinical trials of other new AR-targeted agents binding to the ligand-binding domain or N-terminal domain are underway. This review focuses on the functions of AR in prostate cancer and the development of CRPC and promising new agents against CRPC.
240 citations
••
Cleveland Clinic1, University of the Western Cape2, Lilavati Hospital and Research Centre3, University of Kent4, University of Miami5, Loma Linda University6, Flinders University7, State University of Campinas8, Aarhus University9, Hamad Medical Corporation10, Harvard University11, University of Melbourne12, Hammersmith Hospital13, Imperial College London14, Union Hospital15, Sohag University16, University of Utah17, Cooper University Hospital18, Autonomous University of Madrid19, Pusan National University20, McGill University21, Department of Urology, University of Virginia22, Sapienza University of Rome23, University Hospital Bonn24, Southern Illinois University School of Medicine25, University of Birmingham26, University of Toronto27, First Affiliated Hospital of Wenzhou Medical University28, Tygerberg Hospital29, Icahn School of Medicine at Mount Sinai30, University of Hasselt31, University of Florence32, Yokohama City University Medical Center33, University of Catania34, University of Santo Tomas Hospital35, University of São Paulo36, ALFA37, Hadassah Medical Center38, Tel Aviv University39, Sheba Medical Center40, Ben-Gurion University of the Negev41, Meir Medical Center42, University of Central Florida43, All India Institute of Medical Sciences44, Manipal Hospitals45, Hacettepe University46, University of Belgrade47, Universiti Teknologi MARA48, University of Sousse49, New York University50, Ravenshaw University51, Ege University52
TL;DR: Oxidation-reduction potential (ORP) can be a useful clinical biomarker for the classification of MOSI, as it takes into account the levels of both oxidants and reductants (antioxidants) and may provide a more targeted, reliable approach for administering antioxidant therapy while minimizing the risk of antioxidant overdose.
Abstract: Despite advances in the field of male reproductive health, idiopathic male infertility, in which a man has altered semen characteristics without an identifiable cause and there is no female factor infertility, remains a challenging condition to diagnose and manage. Increasing evidence suggests that oxidative stress (OS) plays an independent role in the etiology of male infertility, with 30% to 80% of infertile men having elevated seminal reactive oxygen species levels. OS can negatively affect fertility via a number of pathways, including interference with capacitation and possible damage to sperm membrane and DNA, which may impair the sperm's potential to fertilize an egg and develop into a healthy embryo. Adequate evaluation of male reproductive potential should therefore include an assessment of sperm OS. We propose the term Male Oxidative Stress Infertility, or MOSI, as a novel descriptor for infertile men with abnormal semen characteristics and OS, including many patients who were previously classified as having idiopathic male infertility. Oxidation-reduction potential (ORP) can be a useful clinical biomarker for the classification of MOSI, as it takes into account the levels of both oxidants and reductants (antioxidants). Current treatment protocols for OS, including the use of antioxidants, are not evidence-based and have the potential for complications and increased healthcare-related expenditures. Utilizing an easy, reproducible, and cost-effective test to measure ORP may provide a more targeted, reliable approach for administering antioxidant therapy while minimizing the risk of antioxidant overdose. With the increasing awareness and understanding of MOSI as a distinct male infertility diagnosis, future research endeavors can facilitate the development of evidence-based treatments that target its underlying cause.
229 citations